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Cutaneous wound repair regenerates skin integrity, but a chronic failure to heal results in compromised tissue function and
increased morbidity. To address this, we have used an integrated approach, using nanobiotechnology to augment the rate of
wound reepithelialization by combining self-assembling peptide (SAP) nanofiber scaffold and Epidermal Growth Factor (EGF).
This SAP bioscaffold was tested in a bioengineered Human Skin Equivalent (HSE) tissue model that enabled wound
reepithelialization to be monitored in a tissue that recapitulates molecular and cellular mechanisms of repair known to occur in
human skin. We found that SAP underwent molecular self-assembly to form unique 3D structures that stably covered the
surface of the wound, suggesting that this scaffold may serve as a viable wound dressing. We measured the rates of release of
EGF from the SAP scaffold and determined that EGF was only released when the scaffold was in direct contact with the HSE. By
measuring the length of the epithelial tongue during wound reepithelialization, we found that SAP scaffolds containing EGF
accelerated the rate of wound coverage by 5 fold when compared to controls without scaffolds and by 3.5 fold when compared
to the scaffold without EGF. In conclusion, our experiments demonstrated that biomaterials composed of a biofunctionalized
peptidic scaffold have many properties that are well-suited for the treatment of cutaneous wounds including wound coverage,
functionalization with bioactive molecules, localized growth factor release and activation of wound repair.
Citation: Schneider A, Garlick JA, Egles C (2008) Self-Assembling Peptide Nanofiber Scaffolds Accelerate Wound Healing. PLoS ONE 3(1): e1410.
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INTRODUCTION
Skin functions to provide a physical and chemical interface that
protects the host against invasion by toxins and microorganisms and
prevents dehydration that can result from loss of barrier function.
The loss of skin integrity and function due to wound injury has led to
efforts designed to better comprehend the molecular and cellular
mechanisms that can optimize wound repair [1,2,3]. The complex
nature of wound healing requires the migration and proliferation of
keratinocytes that are temporally-regulated by numerous growth
factors and their receptors that are upregulated in the wound
environment [4,5,6]. The complexity of the wound environment has
been recreated in human, bioengineered in vitro 3D tissues known as
human skin equivalents (HSE), that have many morphologic and
phenotypic properties of human skin. Adaptating HSEs to study
wound reepithelization has demonstrated several key responses
including cell proliferation, migration, differentiation, growth factor
responsiveness and protein expression that mimic the response to
wounding seen in human skin [7]. In light of this, we used HSEs to
study the effect of a new growth factor-releasing biomaterial on
wound reepithelialization.
As a mediator of wound repair, Epidermal Growth Factor (EGF),
isinvolved inepidermal regeneration by stimulating the proliferation
and migration of keratinocytes at the wound edge [8,9,10], through
its interaction with high affinity receptors on both fibroblasts and
keratinocytes [11,12]. EGF is thought to playa critical roleinwound
repair during the first few days after injury, until wound
reepithelialization is complete. Due to its relatively short half-life of
one hour [13] and its turnover results in loss of occupied receptors
anddecreasedactivity[12],itisnecessarytoapplyEGFfrequentlyto
a wound to maintain an effective local concentration during
initiation of wound healing [13]. Therefore, topical EGF application
that would result in the sustained flux of EGF into the wound
environment would be a very effective way to locally deliver EGF.
To achieve this therapeutic goal, it would be optimal to deliver
biologically-meaningful doses of EGF in a wound dressing. Such a
bioactive dressing should fulfill several criteria for its optimal
function: 1) biocompatibility in the absence of cytotoxicity, 2) easily
applied to the wound, able to conform to the wound surface, and
easily removable after healing, 3) provides a moist environment and
protects the wound against dehydration, 4) allows gas exchange
between the wounded tissue and the external environment, 5)
biofunctionalized to allow the slow release of bioactive agents.
In consideration of these criteria, we have studied if a novel, self-
assembling peptide (SAP) nanofiber scaffold combined with EGF,
could serve as a bio-active wound dressing. SAP nanofibers have
already been shown to serve as excellent materials for a variety of
controlled, molecular-release applications [14,15]. The individual
nanofiber consists of ionic, self-complementary peptides with 16
amino-acids (RADA16-I, Ac-RADARADARADARADA-CONH2)
that undergo self-assembly into hydrogels containing 99.5% w/v
water when exposed to physiological media or salt solution.
These scaffolds closely mimic the structure and porosity of
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diffuse in and out of the scaffold at very slow rates [15]. A
wound dressing comprised of SAP scaffolds could be optimized
by directly molding it to the wound surface as a hydrogel.
In the present report, we have used wounded HSEs to study the
capacity of SAP scaffolds that are combined with EGF, to modulate
the wound healing rate in tissues that closely mimic the human
wound response in vivo. We found that EGF is released from the
hydrogel only when it is in contact with the wound. Released EGF
increased the rate of wound closure by more than 3.5 fold when
compared to wound closure under an SAP scaffold without EGF.
Moreover, the increase in reepithelialization due to SAP-EGF was
mostly due to cell proliferation as demonstrated by BrdU incorpor-
ation. These results demonstrate that this new bioactive material has
many properties that would allow it to be effectively applied directly
to a wound to accelerate reepithelialization of non-healing, chronic
wounds and has significant potential as a wound repair agent.
RESULTS
Design of Self-assembling peptides to incorporate
EGF
Figure 1 depicts the sequence of the SAP RADA16-I that has been
used for this study. The self-assembling peptide scaffold is
composed of short, 8- to 16-residue (<2.5–5 nm in length)
peptides which are chemically synthesized and form extremely
stable b-sheet structures in water [16]. The scanning electron
microscopy image shows the scaffold after the assembly of all of
the polypeptides (Figure 1). These peptides not only self-assemble
to form stable nanofibers, but also form higher-order nanofiber
scaffolds, namely hydrogels with high water content (.99.5 (wt/
vol)% water). The gelation process is charge dependent,
accelerated either by changing to a neutral pH or by adding
physiological concentration of salt solutions.
Preparation of the HSE for the Wound healing
model
Immediately after establishing a full-thickness, incisional wound in
HSEs, epithelium at the wound edges underwent a sequence of
coordinated temporal and spatial events that resulted in wound
reepithelialization. Figure 2 presents a schematic diagram
depicting construction of HSEs that have been adapted to study
the response of wounded keratinocytes and to analyze the tissue
phenotype during reepithelialization. We found that SAP
nanoscaffolds could be formed directly on wounded or non-
wounded control HSEs by adding a drop of peptide solution
directly onto the upper surface of these tissues. Scaffolds rapidly
formed a gel in less than 30 min and completely covered the
wound surface (Figure 2, F and G) by filling the wound incision.
Figure 1. A designer self-assembling peptide nanofiber scaffold. A single peptide, approximately 6 nanometers, is shown. Thousands of peptides
self-assemble to form a single nanofiber, trillions of peptides or billions of nanofibers form the scaffold that contains <99.5% water and 0.5% peptide
materials [16]. Positive and negative charges are labeled in blue and in red, respectively.
doi:10.1371/journal.pone.0001410.g001
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Before testing the effect of SAP-EGF in a wound, we first studied
the rate of EGF release into the media supernatant when sampled
at 1, 2, 3, 4, 8, 24, 40, 48 hours. As shown in Figure 3, no released
EGF was detected in the supernatant by ELISA, demonstrating
that the protein remained in the scaffold and was not released
when the SAP was incubated in PBS.
To determine if EGF release occurred in the wound
environment, SAP scaffolds were applied to the surface of HSEs
after wounding and supernatants were collected at these same
times. Under these conditions, EGF was detected in the media
supernatant by ELISA and the percentage of EGF released from
the RADA16-I gel over a 48 hour period was calculated (Figure 3).
The EGF release profile was biphasic as there was a large initial
release of EGF that was followed by a phase in which EGF was not
released. The amount of EGF released (6.55 mg) reached a plateau
by 24 hours and totaled 65.5% of the EGF that was present in the
SAP. Our observations that EGF was only released when
RADA16-I scaffolds were in contact with the wounded tissue,
highlights the importance of intimate tissue contact with the
wound environment in the release process.
Accelerated Wound Reepithelialization by EGF
Released from SAP
Tissues were harvested 24 and 48 hours after wounding and
stained using hematoxylin and eosin for morphological analysis.
Figure 4 C demonstrates the means by which wound closure was
evaluated by measuring the distance between the wound edge and
the tip of the epithelializing tongue on each side to assess the
percentage of wound closure. To evaluate the effect of EGF on
wound re-epithelialization, we compared wound closure of control
tissues in which no RADA was added to the wound surface
(Figure 5A) to either 1% RADA without EGF (Figure 5B) or
Figure 2. Construction of composite organotypic co-culture wound healing model. A) Schematic drawing of stratified keratinocyte sheet growing
on contracted collagen matrix containing fibroblasts (Layer II). This skin equivalent culture rests on a semi-permeable membrane and is nourished
with medium from below, thus being exposed to an air-liquid interface. A wound is formed by punching a hole through the epithelium and collagen
matrix. B) the wounded culture is transferred onto a second collagen matrix that has undergone contraction (Layer I). C) the resultant composite co-
culture consists of two layers of contracted matrix and one layer of epithelium. Wound edges are seen at the transition zone from layer I to layer II
and are noted with arrows. D) reepithelialization occurs as wounded keratinocytes migrate onto the collagen in layer II and is then followed by
stratification of the tissue to reconstitute a fully stratified epithelium that covers the wound bed. E is a picture of the wound as depicted in C. on top
of the wound a drop of self-assembling peptide containing or not the protein is added (scheme F). G is a picture of the wound covered by the drop of
peptide stained with comassie blue.
doi:10.1371/journal.pone.0001410.g002
Figure 3. Percentage of EGF released from the RADA16-I gels, (X) when the gel is in contact with the wound, and when the gel is put in PBS (&).
doi:10.1371/journal.pone.0001410.g003
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control wound and the wound covered with the SAP scaffold had a
similar response characterized by a short epithelial tongue that
initiated migration at the wound edge. However, a significant
increase in the rate of reepithelization was observed when control
wounds without EGF were compared to wounded tissues covered
with RADA16-I containing EGF. In order to quantify wound
closure, we calculated the percentage of reepithelialization after
24 hours (black boxes) and 48 hours (grey boxes) (Figure 6). We
showed that wounds covered with the SAP scaffold containing
EGF had undergone a 3-fold greater degree of reepithelization
than either the control or RADA16-I wounds. 48 hours after
wounding this difference was even greater as wounds treated with
EGF showed 6064% closure, whereas control and the RADA16-I
only exhibited wound closure of 963% and 1463%, respectively.
Our observation that SAP hydrogel alone increases wound healing
rates could be explained by the fact that the presence of the SAP
offers a moist and protected environment that supports early cell
migration and wound closure. We also tested a positive control by
addingEGF(100 mg/ml)directlytotheculturemedium.Inresponse
to this type of EGF delivery, the wound was closed by 5765%, thus
showing no significant differences with the SAP containing EGF.
Figure 4. Hematoxylin and Eosin staining of wounds (A,B) shows epithelial tongues migrating across the wound bed to close the wound. Ci sa
schematic figure of the wound. The distance between the wound edges and between the epithelial tongues is measured to determine the
percentage of wound closure. The scale bar in A,B is 500 mm, on figure C the scale bar is 100 mm.
doi:10.1371/journal.pone.0001410.g004
Figure 5. Hematoxylin and Eosin staining of the wound after 48 hours (A,B,C). Control tissues where nothing is added on top of the wound (A), are
compared to wounds covered with a drop of RADA16-I (B and with a drop of peptide solution containing the growth factor EGF (C). The scale bar is
500 mm for wounds. For the inserts the scale bar is 100 mm.
doi:10.1371/journal.pone.0001410.g005
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released when in contact with the wound had accelerated wound
closure as efficiently as EGF delivered in the media.
Increased reepithelization linked to SAP-EGF
To assess the phenotypic properties of tissues following wounding
in the presence and absence of SAP-EGF, we studied the
expression and distribution of the basement membrane protein
Laminin 5, as well as proliferation and apoptosis of cells in the
epithelial tongues. Figure 7 depicts the immunostaining of the
tissues 48 hours after wounding when grown in the presence of
SAP’s containing EGF (10 mg/mL). Localization of keratinocyte-
derived laminin 5 demonstrated a normal distribution beneath
epithelial tonghes at the epithelial-connective tissue interface when
wound healing was accelerated by bioactive nanoscaffolds, that
was similar to control wounds. In situ TUNEL assay showed that a
very small number (1.260.3%) of apoptotic basal cells were
present in the wound epithelium that was covered with the SAP-
EGF that were similar to control wounds control wounds
(0.860.5%) (non significant differences as assessed by Student’s
t-test). In addition, there were no apoptotic cells in the part of the
epithelial tongue in contact with the SAP, demonstrating that the
SAP’s are not cytotoxic and do not induce cell death when in
contact with the tissues. To measure the proliferation of
keratinocytes in the epithelial tongue and in the wound margin,
wounded tissues were pulsed with BrdU 6 hours prior to
termination of the experiment and numbers of BrdU-positive
nuclei were counted in triplicate samples following IHC with a
BrdU antibody. We determined that the percentage of BrDU-
positive cells was 1864% when wounds were treated with
SAP+EGF, whereas only 763% of cells were proliferating in
control tissues and 664% in those treated with RADA16-I. The
presence of EGF thus leads to an increase in cell proliferation that
may be linked to the greater degree of wound closure seen upon
application of RADA-EGF to the wound.
DISCUSSION
Integrated efforts by tissue engineers and biologists have facilited
the development of a new generation of biomaterials that combine
suitable physico-chemical properties with biocompatibility, tissue
integration and bioactivity. Among the new generation of
materials, self-assembled peptides (SAP) are biologically-inspired
material scaffolds that have been shown to meet these three
criteria [17]. In the current study, we have advanced the use of
SAPs by demonstrating the biological activity of peptides
incorporated into the scaffold and by using the altered amino
acid sequences containing the RAD motif: RADA16-I, RADAR-
ADARADARADARADA that are similar to the ubiquitous
integrin receptor-binding site RGD [18,19,20] that have previ-
ously shown to elevate cytocompatibility and biointegration [21].
SAP scaffolds consist of alternating amino-acids that contain
50% charged residues [17,22] and are characterized by their
periodic repetition of alternating ionic hydrophilic and hydropho-
bic amino-acids that spontaneously form b-sheets that have distinct
polar and non-polar surfaces. The gelation process can be
accelerated by changing to a neutral pH or by adding physiological
concentrations of salt solutions. Advantages of SAP nanofiber
hydrogels include their biocompatibility [21,22], their capacity to
efficiently respond to external stimuli under physiological condi-
tions and an ability to maintain a high water content (ie 99.5% w/v)
that may allow for the diffusion of a wide range of molecules while
preventing dehydration of adjacent tissues. We have significantly
advanced the potential therapeutic application of these scaffolds by
showing that these properties allow their adaptation to cutaneous
wounds to serve as a bioactive wound dressing. Significantly, when
combined with EGF, these SAPs have been shown to augment
healing of cutaneous wounds in 3D human skin equivalents (HSE)
that mimic their in vivo counterparts.
The future use of SAP-EGF for wound therapy is further
advanced by previous studies demonstrating the lack of immuno-
genicity and inflammation of implanted SAP scaffolds in rat,
rabbit, goat, and hamster models (data not published). Biodegra-
dation products of SAP do not induce toxicity in vivo, as 14C
carbon radiolabeled RADA16-I, has been shown to be completely
eliminated after degradation in rabbit model (data not published).
These studies have been shown that a number of mammalian cell
types, including human dermal fibroblasts, human keratinocytes,
rat hepatocytes, mouse and rat neuronal cells, adhere to and
integrate into SAP peptides [23,24], and support cell proliferation
and differentiation in vitro [23,24]. Linked to our findings that
SAP-EGF accelerates wound reepithelialization, these previous
studies suggest that wound coverage with SAPs may enable dermal
responses as well, such as the early organization and remodeling of
the provisional wound matrix. Thus, the biocompatibility and lack
of cytotoxicity induced by SAPs, combined with our observations
that SAP did not induce apoptosis of wound keratinocytes in
contact with them support their future application as wound
dressings during the early stages of repair.
Most studies on wound healing have been conducted using 2D
cultures (for review see [25]) that use scratch-wounding of a cell
monolayer to monitor cellular response to injury. While these
studies have allowed elucidation of the cellular factors involved in
Figure 6. Percentage of wound closure after 24 hours (black bars) and 48 hours (grey bars). Data points are average of N=7 and error bars
represent6SD.
doi:10.1371/journal.pone.0001410.g006
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well as in response to ECM proteins such as collagens, fibronectin,
vitronectin and laminin [26,27] and/or polypeptide growth factors
[28,29,30], these simple cultures lack the complexity of the wound
healing microenvironment in vivo. It is known that biologically-
meaningful signaling pathways, mediated by linking of adhesion
and growth, function optimally when cells are spatially organized
in 3D tissues but are uncoupled and lost in 2D culture systems
[31]. Therefore, it was essential in the present study to more fully
simulate wound repair by testing the wound response to SAP in
human tissues which display the architectural features seen in
cutaneous tissues in vivo in order to further understand the function
of SAP-EGF in reepithelialization of wounded epithelium. To
accomplish this, we have adapted SAPs to study reepithelialization
and wound response in a tissue that mimics the temporal and
spatial events that occur following wounding of human skin
[32,33,34]. By incorporating SAP into these 3D tissue models, we
have demonstrated efficacy and safety findings that strongly
support its use as a future therapeutic wound healing agent.
SAP nanoscaffolds have been previously loaded with different
types of small molecules [14,15] that demonstrated slow release
from the scaffold. However, no experiments have reported the
release or activity of larger (.850d) and electrically charged
molecules such as growth factors after incorporation into SAPs.
Since the role of these scaffolds has never been tested in wound
repair, we decided to load SAP scaffolds with a growth factor and
to test its role in enhancement of wound healing. We chose to test
the response of wounds to EGF, as it has previously been shown to
have an effect on wound closure by altering cell motility and
proliferation [1,35]. EGF has been shown to act directly at the
wound site [9,36] and similar responses have been observed when
EGF is provided directly to the wound by the animal through
saliva [37]. The fact that, in our experiments, EGF is topically
delivered directly to the wound strongly supports the use of SAPs
in this application as it mimics the biological release of this growth
factor from endogenous sources in the wound environment. This
effect is emphasized by our observation that EGF is released from
the SAP gel only when the gel is in contact with the HSEs. This
Figure 7. Control RADA16-I covered and RADA16-I-EGF-covered (10 mL/mL), specimens were immunostained for Laminin 5. The in situ TUNEL
assay was performed on wounded tissues and apoptotic cells are seen (FITC-green). The scale bars are100 mm. Graphics demonstrate the percentage
of BrdU-positive cells that were counted in 3 sections per sample.
doi:10.1371/journal.pone.0001410.g007
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enzymes such as proteases that are secreted into the wound to
remodel the ECM leading to the subsequent release of EGF. Such
active proteases are secreted from the underlying tissues [1,38] and
from the epithelial tongue itself, as previously demonstrated in the
HSE [7]. Our observations demonstrate that a threshold dose of
EGF was necessary to induce a wound healing response, as the
EGF effect was detected only in the presence of 10 mg/mL of EGF
in the SAP gels and was similar to the controls when the amount of
EGF loaded in the SAP gels was 1 mg/mL (data not shown).
It is now clear that the coordinated effects of multiple growth
factors are needed to direct wound closure in order to avoid
undesirable responses such as keloid formation and scarring [39].
By demonstrating the efficacy of scaffold-mediated delivery of a
topically-acting growth factor, the incorporation of multiple,
synergetic growth factors into SAPs may prove to be feasible for
topical wound therapy. For example, since wound infection is
often linked to chronicity of wound repair, it may be possible to
utilize multi-functionalized SAPs that incorporate antimicrobial
molecules that could both provide anti-bacterial factors, as well as
wound healing stimulants such as EGF, to provide wound
protection while stimulating wound closure. Such multi-functio-
nalized bio-active nanomaterials will greatly advance the field of
wound healing and require future testing in biologically-relevant,
in vitro 3D tissue models and in vivo.
MATERIALS AND METHODS
Preparation of Peptide Nanofibers
The peptide RADA16-I, [COCH3]-RADARADARADARADA-
[CONH2] (molecular weight 1,712), was commercially synthesized
and purified (Massachusetts Institute of Technology Biopolymers
Laboratory). The solution of RADA16-I was prepared by dissolving
the peptide powder with Milli-Q water. Final concentration of the
peptide was 6 mM or 1% (10 mg/ml). The peptide solution was
sonicated for 2 hours min with an ultrasonic cleaner (50T, VWR
Scientific) before each measurement at the maximal power setting.
The human recombinant EGF (Invitrogen-Gibco) was added after
sonication at two different concentrations (1 mg/ml or 10 mg/ml)
before the experiments. The peptide solution was sonicated for
2 hours before being put in contact with the wound to trigger
gelation. EGF was added to the peptide solution after that sonication
steptoavoidanymodification inthe protein structure,wellmixed by
aspiring refouling. We added 100 mL of peptide solution on top of
the wounded HSE.
Cells
Human dermal fibroblasts, HDF, used for skin–equivalent cultures
and scratch wound healing assay were derived from newborn
foreskins using a combination collagenase and Trypsin/EDTA as
previously described [40]. HDFs were grown in DMEM (Gibco,
BRL) supplemented with 10% fetal bovine serum (Hyclone
Laboratories), Penicillin—streptomycin (Sigma), and HEPES
(Sigma). Cells were usually seeded at a density 5610
4 cells/ml
(,10% confluent) for extended cell passage and cultures were
sequentially passaged when cell density reached confluence.
Normal human keratinocytes (NHK) were isolated from newborn
foreskin by the method of Rheinwald and Green [41] and
maintained in keratinocyte medium described by Wu et al. [42].
Cultures were established through trypsinization of foreskin
fragments and grown on irradiated 3T3 fibroblasts. 3T3 cells
were maintained in DMEM (Gibco, BRL) containing 10% bovine
calf serum (Hyclone Laboratories). All cells were grown at 37uCi n
7.5% CO2.
Fabrication of human skin-equivalent wound
healing model
Skin-equivalent cultures were prepared and wounded in vitro as
previously described [43]. Briefly, to construct the collagen matrix,
HDF cells were added to neutralized Type I Collagen (Organo-
genesis, Canton, MA) to a final concentration of 2.5610
4 cells/ml;
3 ml of this mixture was added to each 35 mm well insert of a 6-
well plate and incubated for 7 days in media containing DMEM
and 10% fetal calf serum until the collagen gel showed no further
shrinkage. At this time, of 5610
5 NHKs were plated directly on a
raised, mesa-like area is seen in the center of the contracted
collagen gel. Cultures were submerged in low calcium epidermal
growth media for 2 days, submerged for 2 days in normal calcium
epidermal growth media and raised to the air-liquid interface by
feeding from below at 37uC in 7.5% CO2. Skin-equivalent cultures
were wounded 7 days after keratinocytes were seeded onto the
collagen matrix. One week before cultures were to be wounded, an
additional collagen matrix was fabricated as described above. This
was used as the substrate onto which the wounded skin-equivalents
were transferred. To generate wounds, the skin-equivalent culture
was removed from the insert membrane using 1.5 cm punch, and
a 4 mm punch was used to incise the epidermis and collagen
matrix. Wounded skin-equivalents were transferred onto the 7d-
old collagen matrix. Wounded cultures were maintained at the air-
liquid interface for 24h, and 48h at 37uC in 7.5% CO2 to monitor
reepithelialization.
Immunofluorescence
Specimen were frozen in embedding media (Triangle Biomedical,
Durham, NC) in liquid nitrogen vapors after being placed in 2 M
sucrose for 2 hr at 4_C. Tissues were serial-sectioned at 6 mm and
mounted onto slides. Tissue sections were washed with PBS,
blocked with 10 lg/ml goat IgG, 0.05% goat serum and 0.2% BSA
vol/vol in PBS without fixation. Sections were incubated with
monoclonal antibody to Involucrin (Abcam, Cambridge, MA) that
was detected with Alexa 488-conjugated goat anti-rabbit IgG
(Molecular Probes, Eugene, OR). Laminin V was detected using
the GB-3 monoclonal antibody [44] directed against the intact
heterotrimeric molecule (gift of Dr. G. Meneguzzi). Slides were
coverslipped with Vectashield containing 1 lg/ml DAPI (Vector
Laboratories) and fluorescence was visualized using a Nikon
Eclipse microscope and double exposure photomicroscopy was
performed using FITC and Texas Red filters.
Proliferation and apoptosis assay
Prior to harvesting, skin-equivalents or collagen gels were labeled
with a 6 h pulse of BrdU (Sigma, St. Louis, MO) at a final
concentration of 10 mM. Tissues were harvested and frozen in
embedding medium (Triangle Biomedical, Durham, NC) after
being placed in 2 M sucrose overnight at 4uC. Frozen tissues were
serially sectioned at 8 mm and stained with monoclonal antibodies
against BrdU (Boehringer-Mannheim, Indianapolis, IN) and
counterstained with DAPI (Vector, Burlingame, CA). For
apoptosis detection, skin specimens were fixed in 10% neutral
buffered formalin and in situ TUNEL assay (Roche diagnostics)
was performed in paraffin sections. Fluorescence was visualized
using a Nikon eclipse 80i microscope equipped with the EXFO
Photonics X-CITE 120 Fluorescence Microscope Illumination
System. Pictures were taken using Diagnostic Instruments SPOT
RT Camera. The number of BrdU-positive cells was determined
and expressed as a percent of total cells in the basal layer. Two
independent experiments with a minimum of 3 observations for
each condition were analyzed.
Bioactive Wound Dressing
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For routine light microscopy, skin-equivalent cultures were fixed in
4% neutral buffered formalin, embedded in paraffin, and serially
sectioned at 8 mm. Sections were stained with hematoxylin and
eosin, visualized and measured using a Nikon eclipse 80i
microscope equipped with Diagnostic Instruments SPOT RT
Camera.
ELISA test assay
The RADA16-I solutions were prepared at 1%, EGF was then
added (at 10 mg/mL) and mixed with the pipette. 100 mLo f
RADA16-I solution containing EGF was put in the bottom of an
eppendorf tube, 900 mL PBS 1X were added on top of the peptide
solution. At different times, 100 mL of PBS were taken and
replaced by fresh PBS. For the in-vitro experiments, 100 mLo f
RADA16-I solution containing EGF were put directly on top of
the wound. In this case 100 mL of medium surrounding the well
with the wound, were taken at different times and replaces by fresh
medium. The samples were then frozen and kept at 220uC until
assayed for the cytokine levels using ELISA kits specific for Human
EGF (Quantikine, R&D Systems, Minneapolis, MN). Serial
dilutions were performed to determine cytokine concentrations
by comparison with the standard according to the manufacturer’s
instruction.
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